Introduction
HIV-1 can be either inhibitory, stimulatory or bifunctional (that is, both inhibitory and stimulatory), indicating that HIV-1 infection and replication in vivo and in vitro is under the continuous regulation of a complex cytokine network produced by a variety of cells. This review outlines the overall interactions between cytokines and HIV-1, considers the mechanisms by which cytokines may contribute to HIV-1 pathogenesis and presents examples of clinical applications of cytokine therapy combined with highly active antiretroviral therapy (HAART) or vaccines.
HIV-1 alters cytokine secretion in vitro and in vivo
HIV-1 infection is associated with dysregulation of cytokine production in vivo. Decreased secretion of specific cytokines and increased production of others contributes to the progression of HIV-associated immune deficiency (Clerici & Shearer, 1993) . Using different experimental approaches, numerous investigators have examined cytokine production by cells from HIV-infected individuals as well as within cultures infected with HIV-1 in vitro (Table 1) .
Interleukins IL-1. IL-1, a 17 kDa protein, is a proinflammatory cytokine produced predominantly by cells of macrophage lineage, and to a lesser extent by B cells, endothelial cells and fibroblasts in response to infections and inflammation (Dinarello, 1997) . There are two biologically active forms of IL-1 (IL-1α and IL-1β). In vitro infection of monocytederived macrophages (MDM) with HIV-1 results in upregulation and constitutive secretion of IL-1 in culture supernatants (Esser et al., 1991 (Esser et al., , 1996 (Esser et al., , 1998 . Similarly, monocytes obtained from HIV-infected individuals display constitutive production of biologically active IL-1α and IL-1β proteins, which is suppressed during the course of antiretroviral therapy (Sadeghi et al., 1995; Baqui et al., 2000) .
IL-2. IL-2, a 14-17 kDa monomeric glycoprotein comprising four α-helices, is a Th1 cytokine produced by CD4 and CD8 T cells. The primary role of IL-2 is to stimulate the proliferation of activated T cells, cytotoxic activity of CD8 T cells and natural killer (NK) cells, as well as inducing B cells and monocyte function (Smith, 1988) . In vitro HIV-1 infection of CD4 T cells results in a significant downmodulation of IL-2 mRNA expression that can be reversed by culturing cells in the presence of antiretroviral drugs (Fan et al., 1997) . Stimulation of peripheral blood mononuclear cells (PBMC), CD8 T cell-depleted PBMC and CD4 T cell lines with HIV-1 envelope glycoprotein (gp160) also reduces IL-2 secretion in vitro (Hu et al., 1994) . Similarly, deficiency of IL-2 production is one of the first immunological defects that can be demonstrated in HIV-infected individuals . IL-2 production by in vitro activated PBMC, isolated from HIV-infected subjects at various stages of disease, is significantly decreased when compared with PBMC obtained from uninfected subjects (Barcellini et al., 1994; Meroni et al., 1996; Meyaard et al., 1996) . IL-2 production is related to CD4 T cell counts and clinical status of the patients. It is significantly decreased in patients with CD4 cell counts of <200 cells/mm 3 compared to those with higher CD4 counts (Hong et al., 1998) .
IL-4.
IL-4, an 18 kDa monomeric protein, is a Th2 cytokine produced predominantly by activated CD4 T cells, but also by NK cells, mast cells and basophils. It stimulates B-cell activation and differentiation, secretion of IgG1 and IgE, Tcell activation and MHC II expression on B cells and macrophages (Paul, 1991) . Several studies have shown that increased secretion of IL-4 is associated with HIV-1 infection in vivo. IL-4 production is upregulated in mitogenstimulated PBMC and CD4 T cells obtained from HIVinfected patients at various stages of disease, including recently infected patients (Barcellini et al., 1994; Maggi et al., 1994) . Unstimulated PBMC from HIV-infected individuals not receiving antiretroviral therapy have detectable IL-4 mRNA expression, which falls to undetectable levels once HAART is commenced (Imami et al., 1999) . Enhanced secretion of IL-4 by HIV-seropositive individuals receiving no antiviral therapy has been recently confirmed by investigators using a sensitive three-colour flow cytometric assay to quantify intracellular cytokine production at the single cell level (Breytenbach et al., 2001) . However, there are conflicting reports regarding the effect of HIV-1 infection on IL-4 production, as reduced or normal IL-4 levels have also been reported in supernatants of cultured PBMC and purified CD4 T cells obtained from HIV-infected individuals (Re et al., 1992; Meyaard et al., 1996) .
IL-6. IL-6, a 26 kDa protein, is a proinflammatory cytokine produced by a variety of cells, including T cells, B cells, macrophages, fibroblasts and endothelial cells, in response to viral or bacterial infection. It has a wide spectrum of activities including B-cell stimulation, monocyte differentiation and induction of IL-4 producing cells (Rincon et al., 1997) . In vitro HIV-1 infection of MDM induces upregulation and constitutive secretion of IL-6 in culture supernatants (Esser et al., 1991 (Esser et al., , 1996 (Esser et al., , 1998 Foli et al., 1997) . Stimulation with HIV-1 glycoproteins gp41 or gp120 increases IL-6 production by the human monocytic cell line, THP-1, and mitogen-activated PBMC, respectively (Takeshita et al., 1995; Capobianchi, 1996) . Similarly, IL-6 Esser et al., 1991 Esser et al., ,1996 Esser et al., ,1998 In vivo Sadeghi et al., 1995; Baqui et al., 2000 IL-2 CD4 T cells In vitro Fan et al., 1997 PBMC, CD4 T cells In vitro -gp160 stimulation Hu et al., 1994 PBMC In vivo Barcellini et al., 1994 Meroni et al., 1996; Meyaard et al., 1996; Hong et al., 1998 IL-4 PBMC, CD4 T cells In vivo Barcellini et al., 1994; Maggi et al., 1994; Imami et al., 1999 No change CD4 T cells In vivo Meyaard et al., 1996 CD4 T cells In vivo Re et al., 1992 IL-6 MDM In vitro Esser et al., 1991 Esser et al., ,1996 Esser et al., , 1998 Foli et al., 1997 THP-1 
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} secretion is increased in the sera of HIV-infected individuals, particularly at the early stages of infection, when compared with HIV-seronegative subjects (Birx et al., 1990; Breen et al., 1990) . CD4 T cells and monocytes from HIVinfected subjects, stimulated with phytohaemagglutinin (PHA) or lipopolysaccaride (LPS), respectively, show enhanced secretion of IL-6 compared with cells from uninfected individuals (Cayota et al., 1992; Baqui et al., 2000) . The spontaneous production of IL-6 has also been observed in B cells obtained from HIV-infected individuals, suggesting that HIV is able to induce IL-6 production from a variety of cells of the immune system (Kehrl et al., 1992) .
IL-8.
The inflammatory and antimicrobial cytokine, IL-8, is produced by macrophages, T cells, neutrophils and endothelial cells in acute and chronic inflammatory states. It is a potent chemotactic factor for T cells, NK cells, neutrophils and basophils (reviewed in (Harada et al., 1994) . IL-8 is upregulated and constitutively secreted following in vitro HIV-infection of MDM (Esser et al., 1991 (Esser et al., , 1996 (Esser et al., , 1998 , but reduced in the chronically infected U937 monocytic cell line (Ohashi et al., 1994) . Elevated levels of IL-8 have been also observed in patients with HIV-1 infection, both in patients' serum (Matsumoto et al., 1993) and bronchoalveolar fluid (Denis & Ghadirian, 1994a) .
IL-10. IL-10, an 18kDa protein, is a Th2 cytokine produced by activated T and B cells, monocytes, macrophages and keratinocytes. It inhibits T cell proliferation, predominantly by suppressing synthesis of Th1 cytokines (including IL-2, IFN-γ), and inhibits macrophage activation and secretion of pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-12, TNF-α) (reviewed in Moore et al., 2001) .
In vitro HIV-1 infection as well as gp120 or gp41 treatment of PBMC, monocytes and MDM results in a significant increase in IL-10 secretion and IL-10 mRNA levels in comparison to uninfected or untreated cells (Borghi et al., 1995; Capobianchi et al., 1996; Schols and De Clerq, 1996; Gessani et al., 1997; Taoufik et al., 1997; Barcova et al., 1998) . However, HIV-1 infection of MDM with M-tropic strains of HIV-1 at various multiplicities of infection has also been shown not to induce significant IL-10 secretion or IL-10 mRNA overexpression (Dereuddre-Bosquet et al., 1997) .
The production of IL-10 increases with HIV-1 infection in vivo. There is increased IL-10 secretion (Ameglio et al., 1994; Barcellini et al., 1994; Meroni et al., 1996) and mRNA expression (Imami et al., 1999) in PBMC obtained from HIV-infected patients at all stages of HIV-1 infection compared to uninfected controls. In patients with advanced HIV-1 infection elevated IL-10 production correlates with increased levels of the pro-inflammatory cytokine, TNF-α, suggesting that a combination of those two cytokines has immunopathological consequences and is related to progression to disease (Rizzardi et al., 1998) . Increased levels of IL-10 have been also observed in bronchoalveolar fluid from HIV-infected patients at all stages of infection when compared to levels in uninfected persons (Denis & Ghadirian, 1994a) .
IL-12.
IL-12, a 70 kDa heterodimeric protein consisting of two polypeptide chains, p40 and p35, produced predominantly by cells of macrophage lineage, plays a significant role in cell-mediated immunity against infections by regulating IFN-γ production and modulating responses of cytotoxic T lymphocytes (CTL) and macrophages (Ma & Montaner, 2000) . HIV-1 infection induces production of IL-12 by macrophages, subsequently leading to enhanced production of IFN-γ by T cells and NK cells (Trinchieri & Scott, 1999) . Stimulation of monocytes and macrophages with gp120 induces IL-12 secretion in the supernatant and expression of IL-12 mRNA of both p35 and p40 subunits (Fantuzzi et al., 1996) . However, PBMC isolated from HIV-infected subjects are deficient in their ability to produce IL-12 when compared with uninfected donors, and unable to upregulate the IL-12 receptor β2 chain in response to mitogenic stimuli, suggesting that IL-12 secretion is modulated differently in monocyte/macrophages infected with HIV-1 in vitro and in PBMC during HIV-1 infection in vivo (Marshall et al., 1999) .
IL-13. IL-13, a Th2 cytokine, is produced by T cells and dendritic cells. It shares a receptor subunit and immunoregulatory functions with IL-4 on B cells, monocytes, dendritic cells and fibroblasts, but not T cells, due to the absence of IL-13 receptors on those cells. IL-13 is required for optimal IgE production by B cells, induces MHC II expression on antigen presenting cells (APC) and regulates inflammation by inhibiting proinflammatory cytokine and chemokine production (reviewed in (de Vries, 1998) . PBMC from HIV-infected individuals activated in vitro via CD3/CD28, secrete significantly lower amounts of IL-13 than uninfected controls (Bailer et al., 1999) . This defect is observed in both CD4 and CD8 T-cell subsets, concurrent with downmodulation of IL-13 mRNA level, and correlates positively with the patient's CD4 T cell count and negatively with HIV-1 viral load (Zou et al., 1997; Bailer et al., 1999) .
IL-16
. IL-16, a 16 kDa homotetrameric cytokine, is produced by CD4 T cells, mast cells and eosinophils in response to stimuli such as mitogens, histamine and serotonin. It chemoattracts T cells, monocytes and eosinophils, and modulates T-cell function by enhancing adhesion and IL-2 receptor α and HLA-DR expression (Krakauer et al., 1998) . IL-16 is a natural ligand for the CD4 receptor and inhibits HIV-1 replication (Maciaszek et al., 1997) . Serum levels of IL-16 in asymptomatic HIV-infected individuals are within the normal range or slightly increased, although a significant reduction in IL-16 secretion occurs with progression of HIV-1 infection when compared with levels in uninfected subjects (Amiel et al., 1999; De Paoli et al., 1999) . IL-2 treatment of HIVinfected individuals significantly enhances production of IL-16 after 2 weeks of therapy (De Paoli et al., 1999) .
Interferons
Interferons (IFN-α, -β and -γ) have a wide variety of antiviral, antiproliferative and immunomodulatory effects, and are capable of inhibiting viral infection in a non-specific manner. IFN-α (produced by leukocytes) and IFN-β (produced by fibroblasts and lymphocytes) are 18 kDa monomers, share a common type I IFN receptor, activate indistinguishable signalling pathways and have the same biological actions (Bazan, 1990) . Their functions include stimulation of CTL-mediated killing by increasing MHC I expression, stimulation of NK cell lytic function, inhibition of viral replication and cell proliferation. IFN-γ, a homodimer glycoprotein consisting of 21-24 kDa subunits, is produced by activated T and NK cells and binds to a distinct type II IFN receptor (Bazan, 1990) . Apart from shared activities with IFN-α and -β, this cytokine also promotes T-and B-cell proliferation, activates mononuclear phagocytes and neutrophils, increases MHC II expression and suppresses IL-4 responses (Le Page et al., 2000) .
IFN-α. Productive HIV-infection of monocytes in vitro
results in reduced production of IFN-α (Gendelman et al., 1990; Perno et al., 1994) , although binding of CD4 on T cells or monocytes with HIV-1 envelope glycoprotein, gp120, has been reported to induce IFN-α production in both cell types (Capobianchi, 1996) . Increased levels of IFN-α in serum (Ambrus et al., 1989; Francis et al., 1992; Bizzini et al., 1999) and cerebrospinal fluid have been reported in HIV-infected individuals with dementia compared with non-demented and uninfected individuals, suggesting that this cytokine may play a role in the pathogenesis of HIV-related dementia (Rho et al., 1995) .
IFN-β.
In vitro HIV-1 infection or gp120 treatment of monocytes of MDM results in the induction of low levels of IFN-β compared with uninfected/untreated cells (Gessani et al., 1997) . HIV-1 infection of MDM in the presence of antibodies against IFN-β results in increased levels of p24 antigen in the culture supernatant, suggesting that IFN-β secreted by MDM after HIV-1 infection treatment effectively inhibits HIV-1 replication (Gessani et al., 1994a) .
IFN-γ.
The literature provides conflicting evidence regarding the effect of HIV-1 infection on IFN-γ production. In vitro HIV-1 infection of CD4 T cells results in a significant downmodulation of IFN-γ mRNA expression, blocked by zidovudine treatment (Fan et al., 1997) , but other investigators report enhanced secretion of IFN-γ in the culture supernatant (Vyakarnam et al., 1990) . The discrepancies may be explained by chemokine receptor usage of the HIV-1 strain, because increased production of IFN-γ by HIVinfected CD4 T cells in vitro has been shown to occur in cells infected with only non-syncytium inducing R5 strains of HIV-1, and not with syncytium inducing X4 strains (Greco et al., 1999) . The production of IFN-γ in HIVinfected individuals decreases with disease progression (Clerici & Shearer, 1993; Hong et al., 1998) . IFN-γ secretion is significantly reduced in the supernatant of PBMC obtained from HIV-infected subjects, and is activated in vitro when compared with those from uninfected persons (Meroni et al., 1996; Meyaard et al., 1996) , and correlates with the patient's CD4 count and negatively with HIV-1 plasma viral load (Bailer et al., 1999) . Downmodulation of IFN-γ production is observed in both CD4 and CD8 T cell subsets, and is associated with reduced IFN-γ mRNA levels (Imami et al., 1999) , as well as reduced numbers of IFN-γ-producing cells (Meyaard et al., 1996) . Treatment of patients who have late stage HIV-1 infection with antiretroviral therapy, including protease inhibitors, results in a significant increase in IFN-γ production, when compared with untreated patients (Kelleher et al., 1999) . However, there are also reports of increased IFN-γ production by cytotoxic T cells derived from blood and cerebrospinal fluid of HIV-infected individuals ( Jassoy et al., 1993) .
Colony-stimulating factors
Granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF, a 23-28 kDa glycoprotein comprising a two-stranded antiparallel β-sheet and four α-helices , is produced by a variety of cell types, including activated T cells, endothelial cells, macrophages and fibroblasts. This haemopoietic growth factor is required for survival, proliferation and differentiation of granulocyte/macrophage progenitor cells and the function of their mature progeny (Armitage, 1998) . In vitro infection of MDM with HIV-1 results in decreased secretion of GM-CSF in comparison with uninfected cells (Esser et al., 1996) . Reduced GM-CSF production occurs in all the cells present in HIV-infected cultures, regardless of their level of infection, as determined by immunocytochemical staining for p24 antigen, which suggests that dysregulation of cytokine production occurs not only in HIV-infected MDM but also in non-infected cells via an indirect mechanism (Esser et al., 1998) . The production of GM-CSF by non-stimulated monocytes from AIDS patients is similar to that of uninfected individuals, although it increases after LPS stimulation (Delemarre et al., 1998) .
Macrophage colony-stimulating factor (M-CSF).
M-CSF, a 40 kDa polyprotein produced by fibroblasts and endothelial cells, specifically stimulates the growth and differentiation of cells of macrophage lineage. In vitro HIV-1 infection induces M-CSF production. MDM productively infected with HIV-1 in vitro produce 5-to 24-fold higher levels of M-CSF than uninfected cells (Gruber et al., 1995; Kutza et al., 2000) . Increased levels of M-CSF have been detected in the cerebrospinal fluid of HIV-infected patients, presumably synthesized by cells of macrophage lineage within the brain (Gallo et al., 1994) .
TNF. TNF (TNF-α and TNF-β), a 17 kDa protein, is a proinflammatory cytokine forming a homotrimer capable of cross-linking TNF receptors (Smith & Baglioni, 1987) . TNF-α is produced by a wide variety of cells, including monocytes, macrophages, T cells, B cells, NK cells, neutrophils and microglia cells, whereas TNF-β secretion is restricted to B cells and T cells. Both TNF-α and TNF-β mediate a broad spectrum of inflammatory and immune responses, although the effects of TNF-β are relatively weaker than TNF-α (Armitage, 1994).
TNF-α. TNF-α is increased in association with HIV-1 infection. HIV-1 infection of PBMC and CD4 T cells in vitro enhances their secretion of TNF-α (Vyakarnam et al., 1990) . Exposure of T cells to anti-TNF-α neutralizing antibody, decreases HIV-1 production (as assessed by p24 antigen release), prevents HIV-induced CD4 T cell depletion in vitro and inhibits NFκB activation, suggesting that autocrine secretion of TNF-α controls HIV-1 replication in primary T cells via NFκB activation (Munoz-Fernandez et al., 1997) . TNF-α is upregulated and constitutively secreted after in vitro HIV-infection of MDM, and also augments the infectivity of macrophages in an autocrine fashion (Esser et al., 1991 (Esser et al., , 1996 (Esser et al., , 1998 Foli et al., 1997; Esser et al., 1998) . Increased levels of TNF-α are found in the sera of HIV-infected individuals, monocytes and PBMC obtained from HIV-infected subjects and cultured in vitro (Lahdevirta et al., 1988; Rizzardi et al., 1998; Baqui et al., 2000) .
TNF-β. HIV-1 replication in PBMC and CD4 T cells is associated with enhanced secretion of TNF-β, similar to that of TNF-α (Vyakarnam et al., 1990) . HIV-specific CTL clones derived from peripheral blood and cerebrospinal fluid of HIV-infected individuals release TNF-β following stimulation with specific antigens (Gag, Env, RT and Nef ) ( Jassoy et al., 1993) , suggesting that increased production of TNF-β in vivo is from HIV-specific CTL.
Chemokines α-Chemokines. CXC chemokines, known as α-chemokines, belong to one of three subfamilies of chemokines defined by their structure and the position of cysteine residues. α-chemokines are distinquished by possessing a non-conserved amino acid separating the terminal cysteine residues. The α-chemokine stromal-derived factor (SDF)-1 is a natural ligand for CXCR4. SDF-1 is a chemotactic factor for resting human T cells and monocytes that is expressed on a variety of tissues including heart, lung, liver, spleen, kidney, brain and muscle. It binds to CXCR4, promotes calcium mobilization and downmodulation of CXCR4 (Bleul et al, 1996) . There are two splice variants of the SDF-1 gene: SDF-1α and SDF-1β, which possesses four extra amino acids at the carboxyl terminus. PBMC obtained from HIV-infected individuals, at both sympomatic and asymptomatic stages of disease, display higher levels of SDF-1 mRNA expression than cells from uininfected individuals (Ohashi et al, 1998) .
β-chemokines. The CC chemokine β subset is characterized by two unseparated terminal cysteine residues. β-chemokines are secreted by a wide variety of cells, including T cells, monocytes, macrophages, fibroblasts and mast cells, bind to seven transmembrane domain receptors and promote chemotaxis, leukocyte trafficking, inflammation and haematopoiesis (Rollins, 1997) . Three of the β-chemokines, macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES have been identified as natural ligands for CCR5, a major co-receptor for M-tropic strains of HIV-1 (Cocchi et al., 1995) .
In vitro HIV-1 infection of CD4 T cells results in increased secretion of MIP-1α and MIP-1β by M-tropic strains of HIV-1, and increased production of RANTES by both M-and T-tropic isolates (Greco et al., 1999) . HIV-1 infection also induces MDM to secrete MIP-1α and MIP-1β, subsequently enhancing chemotaxis and activating resting T cells (Schmidtmayerova et al., 1996; Swingler et al., 1999) . Exposure of monocytes and MDM to gp120 or interactions between soluble CD40 ligand and CD40 on MDM, also stimulate the production of MIP-1α, MIP-1β and RANTES in a dose-dependent manner (Kornbluth et al., 1998; Fantuzzi et al., 2001) . Similarly, activated CD8 T cells or PBMC obtained from HIVinfected individuals produce increased levels of MIP-1α, MIP-1β and RANTES (Cocchi et al., 1995 (Cocchi et al., , 2000 Garzino-Demo et al., 1999) . Elevated levels of β-chemokines are found in the plasma of HIV-infected individuals at different stages of infection (Malnati et al., 1997; Vicenzi et al., 1997) , although other investigators report no difference in serum concentrations of all three β-chemokines between HIV-infected and uninfected individuals (Kreuzer et al., 2000) . Poli et al., 1994b; Granowitz et al., 1995; Kinter et al., 1995 IL-2 PBMC, T cell line In vitro Foli et al., 1995; Weissman et al., 1996; Al-Harthi et al., 1998 PBMC In vivo Kinter et al., 1995 Monocytes, MDM, PBMC, In vitro Kazazi et al., 1992; Naif et al., 1994 Naif et al., ,1997 U937 Foli et al., 1995 Monocytes, MDM In vitro Novak et al., 1990; Schuitemaker et al., 1992; Wang et al., 1998 IL-6 PBMC, MDM, U1
In vitro Poli et al., 1990 Poli et al., ,1994b Poli & Fauci, 1992 Poli et al., 1989 Poli et al., ,1994b Shirazi & Pitha, 1992 ; T cells Fan et al., 1994; Gessani et al., 1994 Plasma In vivo Schnittman et al., 1994 IFN-γ Monocytes, MDM In vitro Denis & Ghadirian, 1994b; Fan et al., 1994; Dhawan et al., 1995; Hariharan et al., 1999 
U1, U937, PBMC, CD4 T cells
In vitro Vyakarnam et al., 1990; Biswas et al., 1992; Han et al., 1996 GM-CSF MDM, U937 In vitro Koyanagi et al., 1988; Schuitemaker et al., Variable 1990; Pomerantz et al., 1990; Perno et al., 1992 MDM In vitro Kornbluth et al., 1989; Hammer et al., 1990 MDM In vitro Matsuda et al., 1995 Di Marzio et al., 1998; Kedzierska et al., 2000a M-CSF MDM In vitro Kornbluth et al., 1989; Kalter et al., 1991; Perno et al., 1992; Matsuda et al., 1995; Wang et al., 1998 TNF-α, TNF-β T cells, MDM, U1 In vitro Folks et al., 1989; Kornbluth et al., 1989; Novak et al., 1990; Naif et al., 1994; Han et al., 1996 SDF-1 PBMC, HeLa-CD4 cells In vitro Oberlin et al., 1996; Bleul et al., 1996; Schols et al., 1997; Yang et al., 1999 MIP-1α, MIP-1β, Monocyte, MDM, PBMC, In vitro Cocchi, 1995; Alhatib et al., 1996;  RANTES migroglial cells Cocchi et al., 1996; Paxton et al., 1996; Dragic et al., 1996; Coffey et al., 1997; Capobianchi et al., 1998; Vicenzi et al., 2000; Kitai et al., 2000 Cytokines alter HIV-1 replication in vitro and in vivo HIV-1 replication is controlled by both viral and host factors. A variety of cytokines have been reported to modulate HIV-1 replication at multiple stages of its life cycle, from binding to the CD4 receptor to budding of virions from the infected cells. Cytokines exert both stimulatory and inhibitory effects on HIV-1 infection and replication in both CD4 T cells and cells of macrophage lineage (Table 2 ).
Interleukins IL-1. IL-1 has been shown to enhance HIV-1 replication in IL-2-stimulated PBMC, MDM, and the U1 latently infected cell line derived from U937 (Poli et al., 1994b; Granowitz et al., 1995; Kinter et al., 1995b) .
IL-2. IL-2 is one of the most potent HIV-inducing cytokines (reviewed in Poli & Fauci, 1992) . In mitogenstimulated PBMC, but not in unstimulated cells, IL-2 induces production of HIV-1 over 7 days in culture compared with cells unexposed to this cytokine (Foli et al., 1995) . IL-2-induced upregulation of HIV-1 replication in PBMC and in IL-2 dependent T cell lines is mediated predominantly through a post-transcriptional mechanism, independent of direct HIV-1 long terminal repeat (LTR) activation (Al-Harthi et al., 1998) . The stimulatory effect of IL-2 on HIV-1 replication can be reversed by antibodies to IL-2 and by IL-10, which blocks IL-2 secretion (Weissman et al., 1996) . Removal of CD8 T cells results in a potent stimulation of the HIV-inductive ability of IL-2 in PBMC or lymph node mononuclear cells obtained from HIV-seropositive donors, suggesting that IL-2 induces CD8 T cells to suppress HIV-1 replication (Kinter et al., 1995a) . IL-2 also inhibits apoptosis induced by cross-linking of gp120 and CD4 receptor in CD4 T cells (Randrizzani et al., 1995; Tuosto et al., 1995) . IL-2 is used in clinical trials in combination with antiviral agents to increase the efficacy of anti-HIV therapy by modification of the immune response. Recent studies show that co-administration of HAART and IL-2 results in increased CD4 T cell numbers without an increase in viral load (Emery et al., 2000; Pandolfi et al., 2000; Pett & Emery, 2001; Tambussi et al., 2001) . Virus cannot be isolated from either the blood or lymph nodes obtained from HIV-infected patients on HAART/IL-2 therapy (Chun et al., 1999) . IL-2/HAART also results in a significant reduction in latently infected resting peripheral blood CD4 T cells (a major reservoir of HIV-1 in vivo), in comparison with patients receiving HAART alone, although prolonged therapy for 2 or more years does not eradicate HIV-1 (Zanussi & De Paoli, 2000) . A combination of HAART/IL-2 with IFN-γ in patients with early HIV-1 infection reduces proviral load and shows evidence of immune reconstitution, but again without eradication of viral reservoirs (Lafeuillade et al., 2001) . IL-2 is also used experimentally in combination with DNA vaccines to augment cellular immune responses. Co-administration of HIV-1 and SIV in DNA vaccines with an IL-2 plasmid in rhesus monkeys results in controlled viremia and prevention of clinical AIDS in contrast to sham-vaccinated monkeys who experience rapid downregulation of CD4 cell counts, high viral load and disease progression (Barouch et al., 2000) .
IL-4.
IL-4 displays both stimulatory and inhibitory effects on HIV-1 replication. IL-4 stimulates HIV-1 production in mitogen-stimulated PBMC, monocytes, MDM and promonocytic U937 cell lines (Kazazi et al., 1992; Naif et al., 1994 Naif et al., , 1997 Foli et al., 1995) . IL-4 induces upregulation of HIV-1 replication in MDM when added at the time of HIV-1 infection, which can be reversed by antibodies to IL-4 (Kazazi et al., 1992) . However, IL-4 treatment of freshly isolated monocytes prior to HIV-1 infection downmodulates HIV-1 entry and subsequent replication, possibly as a result of reduced surface expression of the CCR5 co-receptor for M-tropic strains of HIV-1 (Schuitemaker et al., 1992; Wang et al., 1998) . These data suggest that the state of maturation of monocytes into macrophages may determine the stimulatory or inhibitory effect of IL-4 on HIV-1 replication, although even this finding is not clear. Others have shown that pretreatment of monocytes with IL-4 for 5 days prior to HIV-1 infection enhances HIV-1 replication, inducing p24 antigen levels up to 230 times that of cells cultured in the absence of IL-4 (Novak et al., 1990) . The reasons for these discrepancies are not known.
IL-6. IL-6 has been reported to enhance HIV-1 replication in IL-2-stimulated PBMC, MDM and the U1 latently infected cell line derived from U937 (Poli et al., 1990; Poli & Fauci, 1992) . IL-6 synergizes with TNF-α in upregulation of HIV-1 production and potentiates the TNF-α-induced transcription of NFκB (Poli et al., 1990 (Poli et al., , 1994b . Treatment of HIV-infected patients with lymphoma using an anti-IL-6 monoclonal antibody had no significant effect on plasma viral load, but reduced B cell-induced production of IgG and IgA (Marfaing-Koka et al., 1996) .
IL-7.
In vitro treatment of CD3-stimulated PBMC with IL-7 results in a significant increase in HIV-1 production (Moran et al., 1993) . Similarly, exogenous IL-7 induces HIV-1 replication in PBMC from asymptomatic HIVpositive patients at proviral HIV-1 DNA and mRNA levels (Smithgall et al., 1996) . Co-vaccination of IL-7 with gp160 in HIV-infected individuals results in expansion of T-cell proliferative responses to HIV-1 Env (Kim et al., 1997) . IL-7 also increases activation and expansion of specific anti-Gag CTL precursors when co-administered to HIV-infected individuals with a vaccinia/HIV-1 based vaccine, suggesting IL-7-mediated upregulation of cytotoxic immune responses in HIV-infected individuals may potentially be of therapeutic value (Ferrari et al., 1995) .
IL-10.
Exposure of primary MDM and the chronically infected U1 cell line to IL-10 decreases HIV-1 replication (Weissman et al., 1994 (Weissman et al., , 1995 Wang et al., 1998) . This effect of IL-10 is macrophage-specific, because treatment of T cells with IL-10 does not alter HIV-1 replication (Kootstra et al., 1994) . The inhibitory effect of IL-10 on HIV-1 replication is associated with its ability to downmodulate production of TNF-α and IL-6 (Weissman et al., 1994) . Immunoblotting demonstrates an accumulation of Gag precursor protein combined with an absence of mature p24 or gp120, suggesting than inhibitory effect of IL-10 occurs at the level of protein processing (Kootstra et al., 1994) .
IL-12.
IL-12 upregulates HIV-1 replication in mitogenstimulated PBMC and the IL-2 dependent T cell lines when compared with untreated cells, predominantly through a post-transcriptional mechanism that is independent of direct HIV-1 LTR activation (Foli et al., 1995; Al-Harthi et al., 1998) . Similar to IL-2 treatment, IL-12 inhibits gp120-induced apoptosis in IL-2-dependent Th1 clone (Randrizzani et al., 1995) . However, IL-12 treatment of HIV-infected MDM decreases reverse transcriptase (RT) activity in culture supernatants, suggesting that IL-12 directly suppresses HIV-1 replication in purified MDM cultures (Akridge & Reed, 1996) . IL-12 is currently being employed as an immunomodulator in HIV vaccine trials to enhance cell-mediated immunity (Ma & Montaner, 2000; Gherardi et al., 2001 ).
IL-13. IL-13 is a potent suppressor of HIV-1 replication in MDM. This cytokine inhibits both virus infectivity and virus production by down modulating CCR5 expression on MDM, blocking the completion of RT and inhibiting replication at the post-transcriptional level (Montaner et al., 1993 (Montaner et al., , 1997 Denis & Ghadirian, 1994b; Wang et al., 1998) . IL-13 in the presence of TNF-α reduces HIV-1 replication of a dual-tropic strain of HIV-1 in MDM, concurrent with down modulation of surface expression of CD4, CCR5 and CXCR4 as well as post-entry viral gene expression (Bailer et al., 2000) . (Lucey et al., 1997; AlHarthi et al., 1998) . IL-15 also enhances HIV-1 production in PBMC obtained from HIV-seropositive individuals (Lucey et al., 1997) . Similar to IL-12, an IL-15 expression plasmid has been found to increase cell-mediated immunity, including CTL activity and HIV-specific DTH responses, induced by an HIV-1 envelope DNA vaccine when co-administered intranasally to mice (Xin et al., 1999) .
IL-15. IL-15 upregulates HIV-1 replication in PBMC and IL-2-dependent T cell lines in vitro

IL-16. IL-16 inhibits HIV-1 entry and replication in CD4
T cells, MDM and dendritic cells (Truong et al., 1999) . IL-16 treatment of CD8-depleted mitogen-activated lymphocytes, obtained from HIV-infected individuals, results in significant inhibition of secreted p24 antigen (Amiel et al., 1999) , and reduces apoptosis of PBMC (Idziorek et al., 1998) . Pretreatment of CD4 T cells with IL-16 results in up to a 60-fold suppression of HIV-1 promoter activity and prevents Tat activation (Maciaszek et al., 1997) . Antiviral effects of IL-16 suggest a potentially beneficial role on the inhibition of HIV-1 replication in vivo, although there are currently no data to support this.
IL-18
. IL-18 stimulates HIV-1 production by up to 30-fold in the chronically infected monocytic cell line, U1, and is associated with nuclear translocation of NFκB (Shapiro et al., 1998) . Co-delivery of IL-18 (with or without IFN-γ) with DNA vaccine constructs enhances antigen-specific humoral and cellular responses in rhesus macaques and mice (Kim et al., 1999; Billaut-Mulot et al., 2001) .
Interferons
Interferons (IFN-α, IFN-β and IFN-γ) are generally considered to protect MDM from productive infection by HIV-1 in vitro, with minimal or no p24 antigen accumulation in the supernatant, and no HIV-1 RNA or DNA in cell lysates (Kornbluth et al., 1989; Denis & Ghadirian, 1994b; Fan et al., 1994; Dhawan et al., 1995) .
IFN-α.
IFN-α is up to 10-20 times less effective than IFN-γ in inhibiting HIV-1 replication in monocytes and in the U937 promonocytic cell line in vitro (Shirazi & Pitha, 1992; Fan et al., 1994) measured by viral protein levels in the culture supernatant and in cell lysates (Shirazi & Pitha, 1992) . Electron microscopy suggests an altered virus assembly, with the production of morphologically altered virus particles and the inhibition of budding of newly formed virions from the cells surface (Poli et al., 1989) . IFN-α inhibits HIV-1 replication at multiple levels, suppressing RT and inhibiting the production of late products of RT (Shirazi & Pitha, 1992) , and preventing transcription of integrated provirus (Poli et al., 1994a) . The level of inhibition of IFN-α depends on the cytokine concentration, duration of exposure to cells in culture, viral strain and multiplicity of infection (Baca-Regen et al., 1994) .
IFN-α was initially used in the treatment of HIV-1 disease, particularly in patients affected by Kaposi's sarcoma (Lane et al., 1988) . However, relatively high doses of IFN-α are required for anti-tumour activity and are not well tolerated by patients. In patients receiving IFN-α, drug intolerance, neutropenia and anaemia were commonly observed (Haas et al., 2000) . IFN-α therapy transiently increases CD4 T cell proliferation and reduces HIV titres. The latter effect is prominent in HIV-infected patients receiving a combination of IFN-α and IL-2 treatment (Schnittman et al., 1994) . Combination therapy of IFN-α2a with zidovudine and zalcitabine transiently enhances plasma viral load decreases but increases toxicity (Fischl et al., 1997) .
IFN-β.
IFN-β is also a potent inhibitory antiviral agent in MDM infected with HIV-1 in vitro. HIV-1 infection of MDM in the presence of antibodies to IFN-β results in a significant enhancement in p24 release, suggesting that HIV-1 infection of MDM induces production of IFN-β in the culture, which in turn downregulates HIV-1 replication in MDM (Gessani et al., 1994b) . Macrophages derived from umbilical cord blood, transduced with a vector carrying the IFN-β coding sequence, are resistant to infection with a M-tropic strain of HIV-1, demonstrating the efficacy on IFN-β-mediated inhibition of HIV-1 replication (Cremer et al., 2000) . Constitutive low production of IFN-β in peripheral blood lymphocytes by transduction of an IFN-β retroviral vector into lymphocytes from HIV-infected individuals also inhibits viral production (Vieillard et al., 1997) .
IFN-γ. IFN-γ reportedly exerts both stimulatory and inhibitory effects on HIV-1 replication in MDM, depending on whether this cytokine is added before or after infection (Koyanagi et al., 1988; Poli & Fauci, 1992; Poli et al., 1994a) . A number of investigators have shown the inhibitory effect of IFN-γ on HIV-1 replication in monocytes and MDM, with reduced p24 antigen in supernatant as well as HIV-1 DNA and mRNA levels (Fan et al., 1994; Denis & Ghadirian, 1994b; Dhawan et al., 1995) . IFN-γ also inhibits viral entry, possibly via downmodulation of surface expression of CD4, the major receptor for HIV-1, although it upregulates the expression of CCR5 and CCR3 co-receptors used by M-tropic strains of HIV-1 (Dhawan et al., 1995; Hariharan et al., 1999) . In U937-derived clones, IFN-γ exerts its inhibitory effect on HIV-1 replication via inhibition of the JAK/STAT signalling pathway in these cells (Bovolenta et al., 1999) .
However, there are also a number of studies in which a stimulatory effect of IFN-γ on HIV-1 infection has been found. Exposure of chronically infected U1 cells to IFN-γ reportedly activates HIV-1 replication, as measured by culture supernatant RT activity, and cell-associated HIV-1 protein and mRNA (Biswas et al., 1992) . Treatment of U937 cells with IFN-γ modestly increases HIV-1 expression, whereas when added in the presence of TNF-α, IFN-γ synergistically potentiates the stimulatory effect of TNF-α (Han et al., 1996) . IFN-γ has also been found to increase HIV-1-induced syncytium formation by up to 10000-fold in PBMC and CD4 T cells infected with HIV-1 in vitro (Vyakarnam et al., 1990) .
In vivo IFN-γ administration is generally well tolerated and augments the anti-bacterial, -fungal and -parasite activities of monocytes, tissue macrophages and neutrophils (Murray, 1996) . IFN-γ treatment of HIV-infected patients has been used successfully as adjunctive therapy in individuals with drug-resistant tuberculosis or Kaposi's sarcoma (Heagy et al., 1990; Murray, 1996) . IFN-γ is currently used experimentally as an adjuvant in vaccine preparations. Coadministration of IFN-γ with DNA vaccine constructs increases antigen-specific antibody responses to HIV-1 in rhesus macaques (Kim et al., 1999) .
Colony-stimulating factors
GM-CSF.
Early studies investigating the effect of GM-CSF on HIV-1 replication reported upregulation of HIV-1 production in both MDM (Koyanagi et al., 1988; Perno et al., 1989; Schuitemaker et al., 1990; Perno et al., 1992; Wang et al., 1998) as well as promonocytic cell lines U937 and U1 (Folks et al., 1987; Pomerantz et al., 1990) . However, other investigators have found either inconsistent (Kornbluth et al., 1989; Hammer et al., 1990) or inhibitory effects of GM-CSF on HIV-1 entry or replication in MDM (Matsuda et al., 1995; Di Marzio et al., 1998) . Recently, we have reported that GM-CSF inhibits HIV-1 replication in MDM in vitro, measured as reduced RT and p24 in the culture supernatant and reduced mRNA expression (Kedzierska et al., 2000a) . Although a number of laboratory variables could contribute to the conflicting data, potential confounders have been extensively examined, with reproduction of assay conditions used by other investigators (Crowe and Lopez, 1997; Kedzierska et al., 1998) , including strain of HIV-1, source/concentration of GM-CSF, timing of incubation with cytokine, maturity (monocyte versus MDM) and strain of HIV-1 used for infection. Regardless of experimental conditions, reduced replication of HIV-1 has been consistently observed, and GM-CSFmediated inhibition of HIV-1 replication can be reversed by the addition of a neutralizing anti-GM-CSF monoclonal antibody (Kedzierska et al., 2000a) . Analysis of CD4 and CCR5 surface expression on MDM using a flow cytometry, suggests that the inhibition of HIV-1 does not occur at the entry level, rather inhibition is at or before the level of transcription. A mutant form of GM-CSF, E21R, which binds only to the α-chain of the GM-CSF receptor does not inhibit HIV-1 replication in MDM, suggesting that GM-CSF inhibits HIV-1 replication via binding to the β-chain of the GM-CSF receptor (Kedzierska et al., 2000a) and subsequent signalling events in the cell (T Warby, unpublished data).
Currently, GM-CSF is rarely used for the treatment of HIV-infected patients due to the conflicting in vitro data, and thus concern regarding potential activation of HIV-1 replication. GM-CSF treatment of HIV-infected patients in the absence of antiretroviral therapy results in increased serum p24 antigen levels and plasma HIV RNA titres (Kaplan et al., 1991; Lafeuillade et al., 1996) . However, when used in combination with effective antiretroviral therapy, GM-CSF has been safely administered to patients without any significant increase in viral load (Yarchoan et al., 1990; Krown et al., 1992; Kedzierska et al., 2000b) . In fact, GM-CSF has been found to increase the activity of antiretroviral drugs (Perno et al., 1992) . Data from two studies of HIV-infected patients receiving antiretroviral therapy and GM-CSF have shown that patients experienced a decrease in viral load and an increase in CD4 counts (Skowron et al; Brites et al., 2000) . Clinical improvement and augmented monocyte phagocytic function against mycobacteria and fungal infections, again without an increase in viral load, has also been reported in patients with advanced HIV-1 infection and drug-resistant opportunistic infections treated with GM-CSF (Vazquez et al., 1998; Kedzierska et al., 2000b) . These data suggest that GM-CSF might be useful in augmenting macrophage function, especially in HIV-infected patients with drugresistant opportunistic infections.
M-CSF.
Pretreatment of MDM with recombinant M-CSF significantly increases HIV-1 production, measured by RT and viral antigen in the culture supernatant on days 7-10 after infection (Kornbluth et al., 1989; Perno et al., 1992) . MDM exposed to M-CSF are at least 400-fold more susceptible to HIV-1 infection than cells cultured in its absence (Kalter et al., 1991) . M-CSF treatment of MDM results in increased HIV-1 entry and replication, possibly as a result of increasing the surface expression of both CD4 and the CCR5 co-receptor for M-tropic strains of HIV-1 (Wang et al., 1998) . M-CSF exposure also results in increased syncytial formation and increased levels of proviral DNA compared with GM-CSF-treated MDM, which inhibited HIV-1 replication (Matsuda et al., 1995) . M-CSF increases HIV-1 production in bone marrow stem cells infected with an M-tropic strain of HIV-1, as assessed by p24 antigen levels in the culture supernatant (Kitano et al., 1991) . Addition of an M-CSF antagonist, anti-M-CSF monoclonal or polyclonal antibodies, or soluble M-CSF receptors dramatically reduces HIV-1 replication in HIV-infected MDM, suggesting that an M-CSF antagonist may prevent infection of monocytes and macrophages in vivo (Kutza et al., 2000) .
Tumour necrosis factors
Both TNF-α and TNF-β are potent activators of HIV-1 replication in T cells and cells of macrophage lineage Kornbluth et al., 1989; Novak et al., 1990; Naif et al., 1994) via the activation of the cellular transcription factor, NF-κB (Griffin et al., 1991) . The exposure of PHA-activated T lymphocytes to TNF-α before HIV-1 infection does not modify HIV-1 entry (Herbein et al., 1996) . TNF-α upregulates production of HIV-1 mRNA in MDM and in the U1 HIV-infected clone of the U937 cell line, peaking 3-4 days after infection (Naif et al., 1994) . The effect of TNF-α is potentiated by IFN-γ (Han et al., 1996) . TNF-α and TNF-β increase HIV-1-induced syncytium formation by up to 10000-fold in PBMC and CD4 T cells infected with HIV-1 in vitro (Vyakarnam et al., 1990) . However, an inhibitory role of TNF-α on HIV-1 entry in MDM has also been reported with TNF-α pretreatment for 3 days before infection, resulting in approximately 75% inhibition of viral entry (Herbein et al., 1996) .
Chemokines α-Chemokines. SDF-1 suppresses cell fusion and infection of T-tropic strains of HIV-1 in PBMC and HeLa-CD4 cells when compared with uninfected cells (Bleul et al., 1996; Oberlin et al., 1996) , but does not affect infection by M-tropic or dual tropic strains of HIV-1 in vitro (Oberlin et al, 1996) . SDF-1 exerts its inhibitory effect via binding to CXCR4 (Schols et al., 1997) and downmodulation of CXCR4 (Yang et al., 1999) . β-Chemokines. β-Chemokines play an important role in modulation of HIV-1 infection . MIP-1α, MIP-1β and RANTES are inhibitors of HIV-1 replication in cells of macrophage lineage (Cocchi et al., 1995 (Cocchi et al., , 1996 Alkhatib et al., 1996b; Coffey et al., 1997) , PBMC (Coffey et al., 1997; Vicenzi et al., 2000) and microglial cells (Kitai et al., 2000) , suppressing M-tropic isolates, but having no effect on T-tropic strains (Cocchi et al., 2000) . Treatment of MDM or T cells with β-chemokines inhibits HIV-1 entry (Cocchi et al., 1995; Dragic et al., 1996; Paxton et al., 1996; Capobianchi et al., 1998) , viral production and uncoating as well as CCR5 expression ( Jiang & Jolly, 1999) .
HIV-1 and cytokines: summary and conclusions
HIV-1 infection at all stages of the disease is associated with chronic immune activation and dysfunctional cytokine production. During HIV-1 infection a shift of Th cell function from Th1 (decreased production of IL-2 and IFN-γ) to Th2 (increased IL-4 and IL-10 serum levels) is thought to play a central role in the immunopathogenesis of the disease. Increased production of proinflammatory cytokines (IL-1, IL-6, IL-8 and TNF-α) are also thought to activate HIV-1 replication and maintain active HIV-1 expression via binding of NF-κB to LTR. This abnormal cytokine profile can be partially reversed with HAART, resulting in increases in IL-2 and IFN-γ secretion (but not IL-4 and IL-10), paralleled by suppression of HIV-1 replication and restored CD4 T cell counts. The use of cytokine therapy coupled to antiretroviral treatment shows clinical benefit in some circumstances and restoration of immune responses.
The studies presented in this review demonstrate that HIV-1 replication is under regulation of a complex and dysregulated network of both HIV-inductive and -suppressive cytokines, together with a variety of viral and cellular factors. IFN-α, IFN-β, IL-10, IL-13 and IL-16 are clearly the HIV-suppressive cytokines, whereas TNF-α, TNF-β, M-CSF, IL-1, IL-2, IL-6, IL-7, IL-15 and IL-18 augment HIV-1 replication. Bifunctional cytokines, such as IFN-γ, GM-CSF and IL-4, reportedly may exert suppressive or inductive effects on HIV-1 infection and replication, possibly depending on the state of differentiation of monocytes and the experimental protocols used by various laboratories. HIV-1 infection and replication can also be modulated by the presence of LPS in cultures, and results should be carefully examined with this in mind. The presence of LPS has been shown to decrease HIV-1 production by MDM infected by HIV-1 in vitro (Kornbluth et al., 1989) , increase viral infectivity of CD4-enriched PBMC population infected with a T tropic but not an M-tropic strain of HIV-1 ( Juffermans et al., 2000) as well as upregulate HIV-1 co-receptors CXCR4 and CCR5 on CD4 T cells and induce the secretion of proinflammatory cytokines IL-1, IL-6, IL-8 and TNF-α (Goletti et al., 1996) . Therefore, there is a complex interplay between cytokines in vivo. The modulation of infection by exposure of cells to specific cytokines in vitro, a reductionist approach, may oversimplify the biological situation. 
